Cargando…

OA14 The role of anifrolumab in treating life threatening systemic lupus erythematosus with severe mucocutaneous involvement

INTRODUCTION: Systemic lupus erythematosus (SLE) refractory to conventional DMARDs and anti-malarials has limited treatment options including rituximab, cyclophosphamide and belimumab. Although not currently licensed for use in the UK, anifrolumab (a monoclonal antibody targeting the type 1 interfer...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldwin, Christopher, Ali, Sasha, Nagra, Deepak, Hannah, Jennifer, Gordon, Patrick, Galloway, James, Wincup, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532103/
http://dx.doi.org/10.1093/rap/rkad070.014

Ejemplares similares